PMV Pharmaceuticals Reports $21.1 Million Net Loss in Q3 2025, Increases R&D Spending

PMV Pharmaceuticals, Inc. reported a net loss of $21.1 million for the third quarter of 2025, compared to a loss of $19.2 million in the same period of the previous year. For the nine months ended September 30, 2025, the company incurred a net loss of $59.7 million, significantly higher than the $35.7 million loss reported for the same period in 2024. The increase in losses is attributed to rising research and development expenses, which totaled $54.1 million for the nine months ended September 30, 2025, up from $44.8 million in the prior year. The company's total operating expenses for the third quarter were $22.5 million, a slight increase from $21.9 million in the third quarter of 2024.

In terms of financial position, PMV Pharmaceuticals reported total current assets of $132.4 million as of September 30, 2025, down from $175.7 million at the end of 2024. The decrease was primarily due to a reduction in cash and cash equivalents, which fell to $36.3 million from $40.9 million, and a decline in marketable securities, which decreased to $92.9 million from $128.6 million. The company’s accumulated deficit also increased to $428.4 million, reflecting ongoing operational losses since its inception.

Strategically, PMV Pharmaceuticals is advancing its lead product candidate, rezatapopt, through clinical trials. The company initiated a Phase 1/2 clinical trial, PYNNACLE, in October 2020, and has received FDA Fast Track designation for rezatapopt. In September 2025, interim data from the Phase 2 pivotal portion of the trial was announced, with plans to submit a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer by the first quarter of 2027. The company has also undergone a restructuring plan that reduced its workforce by approximately 30% to streamline operations and reduce costs.

Operationally, PMV Pharmaceuticals has not generated any revenue from product sales and does not expect to do so in the near future. The company continues to rely on external funding to support its research and development activities. As of September 30, 2025, PMV had approximately $113.8 million available for future issuances of common stock under its at-the-market offering program. The company anticipates that its cash, cash equivalents, and marketable securities will be sufficient to fund operations until the end of the first quarter of 2027, although it may need to secure additional funding to continue its development efforts.